Skip to main content

Animations

MJFF Publications

5461 - 5470 of 7916 Results
Title
Year
  • Year
  • 2018
  • 2018
  • 2018
  • 2018
  • 2018
  • 2018
  • 2018
  • 2018
  • 2018
  • 2018
  • RESTRICTED
    Title: The Therapeutic Potential of Metformin in Neurodegenerative Diseases
    Journal Name: Frontiers in Endocrinology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fendo.2018.00400
    Citation Count: 209
  • RESTRICTED
    Title: A new model to study cell-to-cell transfer of αSynuclein in vivo
    Journal Name: Biochemical and Biophysical Research Communications
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.bbrc.2018.07.053
    Best OA location URL:
    Citation Count: 8
  • OPEN
    Title: NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson’s disease
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-018-0061-5
    Citation Count: 134
  • OPEN
    Title: The GBA p.Trp378Gly mutation is a probable French‐Canadian founder mutation causing Gaucher disease and synucleinopathies
    Journal Name: Clinical Genetics
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1111/cge.13405
    Citation Count: 9
  • OPEN
    Title: Loss of Sarm1 does not suppress motor neuron degeneration in the SOD1G93A mouse model of amyotrophic lateral sclerosis
    Journal Name: Human Molecular Genetics
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1093/hmg/ddy260
    Citation Count: 50
  • RESTRICTED
    Title: Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review
    Journal Name: Clinical Neuropharmacology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1097/wnf.0000000000000296
    Best OA location URL:
    Citation Count: 11
  • OPEN
    Title: The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Nav 1.6
    Journal Name: Experimental Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.expneurol.2018.07.005
    Citation Count: 36
  • OPEN
    Title: Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
    Journal Name: Frontiers in Neurology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fneur.2018.00560
    Citation Count: 51
  • RESTRICTED
    Title: MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson’s Disease Patients
    Journal Name: Molecular Neurobiology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s12035-018-1219-1
    Best OA location URL:
    Citation Count: 17
  • OPEN
    Title: Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning
    Journal Name: Scientific Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41598-018-28840-w
    Citation Count: 46
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.